The constitutive activation of PI3K/AKT/mTOR has been reported in 50–80% of AML patients, in correlation with a decrease in overall survival [54]; thus, key components of this pathway have been considered as possible targets for AML treatment. This evidence concerns the gene MTOR and acute myeloid leukemia.